Rosen Law Firm Files Securities Class Action Against Aldeyra Therapeutics

Lawsuit alleges company misled investors about drug trial results.

Mar. 31, 2026 at 3:13am

Got story updates? Submit your updates here. ›

A photorealistic studio still-life featuring a stack of legal documents, a gavel, and a calculator on a clean, monochromatic background, symbolizing the legal and financial implications of the securities class action lawsuit.A legal battle over alleged financial deception casts a shadow over the future of a pharmaceutical company.NYC Today

The Rosen Law Firm has filed a securities class action lawsuit against Aldeyra Therapeutics, Inc. on behalf of investors who purchased the company's stock between January 1, 2025 and March 15, 2026. The lawsuit alleges that Aldeyra Therapeutics made false and misleading statements about the results of clinical trials for one of its drug candidates, causing the stock price to artificially inflate before a subsequent decline.

Why it matters

Securities class action lawsuits can have significant financial and reputational impacts on public companies. This case highlights the importance of transparency and accurate disclosures for publicly traded pharmaceutical firms, especially around the progress and outcomes of clinical trials for new drug candidates.

The details

The lawsuit alleges that Aldeyra Therapeutics misled investors by claiming its drug candidate for the treatment of a certain eye condition had met the primary endpoint in a late-stage clinical trial, when in fact the drug had failed to demonstrate statistically significant improvement over the placebo. The company's stock price dropped sharply after the true trial results were revealed.

  • The class action lawsuit was filed on March 30, 2026.
  • The lawsuit covers the period from January 1, 2025 to March 15, 2026.

The players

Rosen Law Firm

A national law firm that specializes in representing investors in securities class action lawsuits.

Aldeyra Therapeutics, Inc.

A publicly traded biopharmaceutical company focused on the development of novel therapies for immune-mediated diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We're committed to holding Aldeyra Therapeutics accountable for its alleged deception of investors.”

— Laurence Rosen, Managing Partner, Rosen Law Firm

What’s next

The court will determine whether to certify the class and allow the lawsuit to proceed as a class action.

The takeaway

This case underscores the importance of pharmaceutical companies providing accurate and timely information to investors, especially regarding the progress and outcomes of clinical trials for new drug candidates. Investors will be closely watching how this lawsuit unfolds.